By Dick, C. and Merrill, J. and Morck, D. and Olson, M., Bovine Practitioner, 1999
Description
Two studies were conducted in a commercial feedlot in Western Canada to determine the dosage of subcutaneous tilmicosin injection required as therapy for bovine footrot. Three hundred and twenty animals showing signs of acute lameness including inflammation and swelling of the skin and tissues of the interdigital cleft, coronet, and/or the distal limb were considered suspect cases of footrot by pen riders and presented to the hospital facility for evaluation. Candidates for enrollment were thoroughly examined to eliminate those cases of lameness caused by foreign objects, sprains, fractures, sole abscesses or other causes of lameness not associated with acute bovine footrot. As animals presented they were randomly assigned to either placebo (saline at 1.5 ml/50 kg body wt), 2.5, 5.0 or 10.0 mg tilmicosin/kg body wt in blocks of four animals (study 1) or to either 2.5, 5.0 or 10.0 mg tilmicosin/kg body wt in blocks of three (study 2). On day 1 (defined as the point in time that the anim al is confirmed for inclusion on the trial and treatment administered), day 2, day 3 and day 4 the animals were scored for lameness, swelling and lesions using a 4 point scale. Treatment was considered successful if on day 4 the animal scored 0 (normal) for lameness and did not require retreatment for footrot in the next 10 days. Cure rates were 15.0, 68.0, 74.0 and 77.0%, respectively, for the placebo, 2.5, 5.0 and 10 mg tilmicosin/kg body weight. There were no significant differences between the 2.5, 5.0 and 10 mg tilmicosin/kg body weight dosages but all were significantly (p<.05) higher than the placebo. There appeared to be a trend to improved efficacy with higher dosages
Two studies were conducted in a commercial feedlot in Western Canada to determine the dosage of subcutaneous tilmicosin injection required as therapy for bovine footrot. Three hundred and twenty animals showing signs of acute lameness including inflammation and swelling of the skin and tissues of the interdigital cleft, coronet, and/or the distal limb were considered suspect cases of footrot by pen riders and presented to the hospital facility for evaluation. Candidates for enrollment were thoroughly examined to eliminate those cases of lameness caused by foreign objects, sprains, fractures, sole abscesses or other causes of lameness not associated with acute bovine footrot. As animals presented they were randomly assigned to either placebo (saline at 1.5 ml/50 kg body wt), 2.5, 5.0 or 10.0 mg tilmicosin/kg body wt in blocks of four animals (study 1) or to either 2.5, 5.0 or 10.0 mg tilmicosin/kg body wt in blocks of three (study 2). On day 1 (defined as the point in time that the anim al is confirmed for inclusion on the trial and treatment administered), day 2, day 3 and day 4 the animals were scored for lameness, swelling and lesions using a 4 point scale. Treatment was considered successful if on day 4 the animal scored 0 (normal) for lameness and did not require retreatment for footrot in the next 10 days. Cure rates were 15.0, 68.0, 74.0 and 77.0%, respectively, for the placebo, 2.5, 5.0 and 10 mg tilmicosin/kg body weight. There were no significant differences between the 2.5, 5.0 and 10 mg tilmicosin/kg body weight dosages but all were significantly (p<.05) higher than the placebo. There appeared to be a trend to improved efficacy with higher dosages
We welcome and encourage discussion of our linked research papers. Registered users can post their comments here. New users' comments are moderated, so please allow a while for them to be published.